Lots of interesting abstracts and cases were submitted for TCTAP 2025. Below are the accepted ones after a thorough review by our official reviewers. Don’t miss the opportunity to expand your knowledge and interact with authors as well as virtual participants by sharing your opinion in the comment section!
TCTAP A-018
In-Hospital and One-Year Outcomes in Cancer Patients Receiving Percutaneous Coronary Intervention (PCI) for Acute Myocardial Infarction (MI)
By Hiteshi K.C. Chauhan, Sohini Sarkhel, Saptarghya Mandal
Presenter
Hiteshi K.C. Chauhan
Authors
Hiteshi K.C. Chauhan1, Sohini Sarkhel1, Saptarghya Mandal1
Affiliation
Fortis Healthcare Limited, India1
View Study Report
TCTAP A-018
ACS/AMI
In-Hospital and One-Year Outcomes in Cancer Patients Receiving Percutaneous Coronary Intervention (PCI) for Acute Myocardial Infarction (MI)
Hiteshi K.C. Chauhan1, Sohini Sarkhel1, Saptarghya Mandal1
Fortis Healthcare Limited, India1
Background
1. Study Objective:
- Group 1: Cancer patients undergoing PCI for acute MI.
- Group 2: Non-cancer patients undergoing PCI for acute MI (control group).
- Inclusion Criteria:
- Adult patients (≥18 years old) diagnosed with acute MI and undergoing PCI.
- Cancer diagnosis (any type of cancer, active or in remission) in Group 1.
- No cancer diagnosis in Group 2.
- Patients must provide informed consent (or consent via legal proxy if necessary).
- Exclusion Criteria:
- Patients with contraindications to PCI.
- Patients with terminal cancer (expected survival <6 months).
- Previous PCI within 6 months for the same indication.
- Patients with life-threatening conditions unrelated to MI or cancer (e.g., end-stage organ failure)
Methods
4. Primary Outcomes:
- In-hospital outcomes:
- Mortality rate
- Major adverse cardiac events (MACE), defined as:
- Death
- Reinfarction
- Stroke
- Target vessel revascularization
- Complications related to PCI (e.g., bleeding, vascular complications)
- Length of hospital stay
- One-year outcomes:
- All-cause mortality
- Cardiovascular mortality
- MACE (similar to in-hospital outcomes)
- Cancer-related outcomes (progression or recurrence of cancer)
- Quality of life assessment (using validated tools such as EQ-5D or SF-36)
- Hospital readmissions due to cardiovascular events
- In-hospital and one-year functional recovery (e.g., New York Heart Association [NYHA] class, functional status)
- Assessment of PCI-related complications (e.g., stent thrombosis, bleeding complications)
- Cancer treatment interactions or delays due to MI or PCI
- Risk of drug interactions or contraindications related to cancer therapies and antiplatelet/anticoagulation therapies used in PCI
- Demographics: Age, gender, comorbidities (diabetes, hypertension, renal function, smoking status, etc.), cancer history (type, stage, treatment history), and other baseline characteristics.
- Acute MI and PCI Details: Type of MI (ST-elevation or non-ST elevation), timing of PCI, type of stents used, procedural success, complications during PCI.
- Cancer Treatment History: Active cancer treatments (chemotherapy, radiotherapy, immunotherapy), recent cancer-related surgeries, cancer remission status.
- Follow-up: In-hospital data collected, then follow-up data at 1, 3, 6, and 12 months (via hospital records, phone surveys, and patient questionnaires)
Results
Would be presented at TCTAP 2025.
Expected Impact:
Expected Impact:
Conclusion
Results would be presented at TCTAP 2025. Expected Impact:Thisstudy aims to provide critical data on the safety and outcomes of PCI in cancerpatients, helping to inform clinical decision-making and the management ofcancer patients who suffer acute MI. The findings could guide clinicalprotocols regarding cancer treatment interactions with PCI and long-term carestrategies for this vulnerable population.